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hPAR2, is a member of the novel family of proteolytically-activated G-protein coupled receptors 
(GPCR) termed Proteinase-Activated Receptors (PAR). Previous pharmacological studies have 
found that activation of hPAR2 by mast cell tryptase, can be regulated by receptor N-terminal 
glycosylation. In order to elucidate other post-translational modifications of hPAR2 that can 
regulate function, we have explored the functional role of the intracellular cysteine, C361. We 
demonstrated, using autoradiography, that C361 is the primary palmitoylation site of hPAR2. 
The hPAR2C361A mutant cell line displayed greater cell surface expression compared to the wt-
hPAR2 expressing cell line. The hPAR2C361A also showed a decreased sensitivity and efficacy 
(intracellular calcium signalling) towards both trypsin and SLIGKV-NH2. In stark contrast 
hPAR2C361A triggered greater and more prolonged ERK phosphorylation compared to that of 
wt-hPAR2 possibly through Gi, since pertussis toxin inhibited this receptors ability to activate 
ERK. Finally, flow cytometry was utilised to assess the rate, and extent of receptor 
internalisation following agonist challenge. The hPAR2C361A receptor displayed faster 
internalisation kinetics following trypsin activation, compared to wt-hPAR2, whilst SLIGKV-
NH2 had negligible effect on internalisation for either receptor.  Palmitoylation plays an 
important role in the regulation of PAR2 receptor expression, agonist sensitivity, desensitisation 
and internalisation. 
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INTRODUCTION
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Post-translational modifications of GPCRs can extensively regulate numerous aspects of their biology 
including cell surface expression, trafficking, folding, signalling, and ligand binding. Examples of 
post-translational modifications known to regulate GPCR function include N-linked glycosylation, 
phosphorylation and palmitoylation [1-2].  Phosphorylation of GPCRs is well known to induce 
receptor desensitisation through the action of second messenger-activated and GPCR kinases on 
serine and threonine residues located on the intracellular and carboxyl tail of the receptors [3]. Such 
phosphorylation results in uncoupling of the receptor from G-proteins through the involvement of -
arrestins which bind to the phosphorylated receptors and target them towards clatherin coated pits 
where the receptor undergoes endocytosis [3]. Following endocytosis, -arrestin can target the 
receptor to  
the mitogen-activated protein kinases (MAPK) signalling pathway [4]. Thus, processes that influence 
-arrestin binding to a GPCR may  govern which signalling pathways are triggered by the receptor. 
Conflicting reports concerning PAR2 activation by tryptase were found to be a result of N-
linked glycosylation [1, 5], thus post-translational modifications of PARs can have a profound 
influence on receptor function and have to date been little investigated. The post-translational 
covalent attachment of lipid moieties is essential for many proteins. The most common lipid 
modification is the post-translational addition of palmitic acid, which also seems to have the most 
wide-ranging effects [6]. Palmitoylation is a thioesterification which often occurs with cyteine 
                                                 
Abbreviations: α-MEM, Dulbecco’s α-modified essential medium; ANOVA, analysis of variance; AP, 
activating protein; CHO, Chinese hamster ovary;  ERK1/2, extracellular signal-regulated kinases; FCS, foetal 
calf serum; GPCR, G-Protein coupled receptor; HA11, influenza haemagglutinin; hPAR2, human proteinase 
activated receptor; MAPK, mitogen activated protein kinase; PTX, pertussis toxin; RT, room temperature. 
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residues 10-14 amino acids downstream of the last transmembrane domain [7].  Using this principal 
we have identified a C-terminal cysteine residue in hPAR2 (C361) as a putative palmitoylation site 
(Figure 1).  The importance of palmitoylation in GPCRs is wide-ranging [2] and has been implicated 
in numerous processes including agonist-induced internalisation [8], and agonist induced down-
regulation [9], but its role varies depending on the GPCR considered.  Proteins can be constitutively 
palmitoylated or may require agonist activation for the modification to occur [10-11]  In this study we 
investigate the role of C361 in various aspects of hPAR2 expression and function. 
 
EXPERIMENTAL 
Materials. 
Human plasma thrombin was purchased from Calbiochem, Merck Chemicals Ltd, (Nottingham, UK). 
Anti-HA11 antibody was purchased from Covance (Harrogate, UK). Sam11 antibody was purchased 
from Zymed (Invitrogen, Paisley, UK). Foetal calf serum (FCS), Dulbecco's α-modified essential 
medium (α-MEM, with ribonucleosides and deoxyribonucleosides), non-enzymic cell-dissociation 
solution, geneticin, penicillin, streptomycin, PBS (without calcium and magnesium) pcDNA 3.1(+) 
and fluo-3 acetoxymethyl ester (fluo-3 AM) were from Invitrogen (Paisley, UK).  All 
oligonucleotides were synthesized by the peptide synthesis facility, University of Calgary (Alberta, 
Canada) or purchased from peptides international (Kentucky, USA). µMACS™ HA11 Epitope Tag 
Protein Isolation Kit were supplied by Miltenyi Biotech (Bergisch, Germany).  Hybond C PVDF 
membrane, hyperfilm x-ray film, peroxidase conjugated goat anti-mouse IgG, Amplify™ and ECL 
was purchased from Amersham Biosciences (Buckinghamshire, U.K.).  All other chemicals and 
reagents were purchased from Sigma (Dorset, UK.) unless otherwise stated. 
 
Expression Vectors. 
The wt-hPAR2 cDNA possessing a C-terminal HA11 epitope (YPYDVPDYA) used in this study has 
been described in detail previously [1]. Human PAR2C361A was generated using the QuikChange 
site-directed mutagenesis kit (Stratagene, Amsterdam, Netherlands), according to the manufacturer's 
instructions.  The engineered mutation in PAR2 was then confirmed by automated DNA sequencing 
(MWG, Germany). 
  
Cell culture and transfection 
The Pro5 Chinese Hamster Ovary (CHO) cell line, that permanently expressed either wild-type or 
mutant hPAR2 receptors, were propagated in selective growth media (α-MEM containing 10% FCS, 
100 units/ml penicillin, 100 ng/ml streptomycin, 250 ng/ml amphotericin B, and 800 µg/ml geneticin) 
5% CO2 at 37
o
C. All cell lines were harvested using non-enzymatic cell dissociation solution. 
Permanent receptor expressing cell lines cells were generated by transfection using the 
LipofectAMINE2000 (Invitrogen, Paisley, U.K.) method, according to the manufacturer's protocol. 
Transfected Pro5 cells were propagated in selective growth medium for two weeks to allow selection. 
Permanently expressing cell-lines were selected by single cell cloning and assessed for receptor 
expression by flow cytometry. 
 
Determination of cell surface expression of hPAR2 wild-type, and hPAR2C361A receptors. 
It has previously been found that in the cell lines used “receptor expression (is) sensitive to 
confluence” [1]. Therefore flow cytometry was used to assess receptor expression.  Cells were grown 
to different levels of confluence and then labelled with Sam11 mouse anti-human PAR2 antibody and 
anti-mouse FITC conjugate before analysing with flow cytometry to assess and match receptor 
expression.  
 
Localisation of Receptor by Confocal Imaging 
Confocal microscopy was used to determine the location of PAR2 and PAR2C361A within the cells.  
Sam11 shows cell surface expression and HA11 shows total cell expression.  For Sam11 staining cells 
grown on coverslips were incubated with Sam11 anti-PAR2 antibody (1μg/ml) at RT for 60 min 
before incubation with FITC conjugated anti-mouse antibody (1μg/ml). For HA11 staining, coverslips 
were  pre-incubated in PBS (1% BSA, 3% Rabbit Serum) for 15 min prior to addition of anti-HA11 
mouse monoclonal antibody (1μg/ml) and incubated at RT for 60 min. Coverslips were then incubated 
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with FITC conjugated anti-mouse antibody (1μg/ml). The slides were then analysed on a confocal 
microscope using an argon laser exciting at 488 nm and detecting fluorescence emissions above 500 
nm. Each experiment consisted of two pictures from each of three coverslip repeats for each treatment 
and a final consensus photo being chosen. 
 
[
3
H]-palmitate labelling and PAR2 immunoprecipitation. 
The constitutive palmitoylation of PAR2 was investigated by detecting [
3
H]-palmitate labelling of the 
receptor.  Wt-hPAR2 and hPAR2C361A expressing Pro5 cell lines were seeded in 100 mm dishes, 
pre-incubated overnight in serum-free medium, and labelled with 1 mCi [
3
H] palmitic acid for 4 h at 
37 °C. After labelling, PAR2 protein from the cell lines was isolated by immunoprecipitation using the 
µMACS™ HA11 Epitope Tag Protein Isolation Kit (Miltenyi Biotech, Bergisch, Germany) as per 
manufacturers protocol. 
Proteins were then resolved on SDS-PAGE in non-reducing conditions and then fixed for 30 
min (isopropanol:water:acetic acid, 25:62:10). Gels were then treated with Amplify™ for 15 min at 
RT before drying under vacuum at 80
oC. The dried gel was then exposed to Hyperfilm™ x-ray film at 
-80
o
C for 24 hours, before developing. 
In order to confirm equal loading of radiolabelled PAR2 protein, immunoblots were 
performed with half of the protein sample used in the palmitate experiments. Briefly 
immunoprecipitated samples were separated on a 10% SDS/PAGE gel before transfer to Hybond C 
PVDF membrane.  The membrane was blocked with 5% non-fat milk powder in PBS/Tween 20 
(0.1%) for 1 h before incubation overnight at 4 °C with the mouse monoclonal anti-HA.11 antibody (1 
in 1000 dilution in PBS/Tween-20 (0.1%) containing 2% non-fat milk) then incubated with 
peroxidase conjugated goat anti-mouse IgG (1 in 1000) for 1 h.  The epitope tagged hPAR2 receptor 
was then visualized using enhanced chemiluminescence (ECL2), and captured on a UVP Epi Chem II 
Darkroom with fluorescence camera and analysed using Labworks v4.5 software.  
 
Calcium signalling assay 
Calcium signalling was performed as described previously [12]. Cells were harvested non-
enzymically and incubated in 1 ml of -MEM containing 0.25 mM sulphinpyrazone and 22 μM Fluo-
3 AM for 25 min at RT on an orbital mixer. Cells were then washed and resuspended in calcium assay 
buffer, (150 mM NaCl, 3 mM KCl, 1.5 mM CaCl2, 10 mM glucose, 20 mM Hepes and 0.25 mM 
sulphinpyrazone) pH 7.4. Fluorescence measurements were performed on a Photon Technology 
International Fluorospectrophotometer (West Sussex, UK), with an excitation wavelength of 480 nm 
and emission recorded at 530 nm.  The signal produced by the addition of a test agonist was measured 
as a percentage of the fluorescence peak height, yielded by the addition of 2 µM calcium ionophore 
(A23187). 
 
ERK1/2 phosphorylation and immunoblots. 
Cells were grown in 6 well plates to a confluence of 40-50% in normal media. Media was then 
replaced with serum-free media and cells incubated overnight. Cells were then treated with agonist for 
a specified time (0, 5, 10, 30, 60 min) before halting treatment and harvesting cells in Laemlli’s 
Sample Buffer (30% glycerol, 140mM Tris pH 6.8, 5% SDS, 7 nM Bromophenol blue, 5 mM EDTA, 
1/20 2-mercaptoethanol). Samples were then incubated at 100
o
C for 5 min prior to analysis by 
western blotting (as described in [
3
H]-palmitate labelling and PAR2 immunoprecipitation) using 
p44/42 MAP kinase Antibody (1 in 1000) and Phospho-p44/42 MAP Kinase Antibody (1 in 1000) 
(Cell Signaling Technology, NEB, Herts, UK). 
 
Receptor Internalisation Assay 
Semi-confluent cells (approx. 40% confluence) were harvested and treated with trypsin (100 nM) or 
the synthetic peptide SLIGKV-NH2 (100 μM) which corresponds to the tethered ligand exposed by 
trypsin cleavage of PAR2, for 0-30min at RT before being placed on ice.  Cells were then washed and 
centrifuged. Pelleted cells were resuspended in cold-PBS and placed on ice for 10 min before 
incubation with Sam11 mouse anti-PAR2 monoclonal antibody (3 μg/mL) for 1 h on ice followed by 
incubation with anti-mouse FITC-conjugated antibody (10 μg/mL) for a further 45 min. Cells were 
then analysed for PAR2 cell-surface expression by flow cytometry (Becton Dickinson, Oxford, U.K.).   
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Statistical Analysis. 
Graphs were produced using Prism Graphpad. For a two dataset comparison of group mean a two-
tailed test was used, when this was to compare two different treatments on the same cell line, or when 
this was to compare two different cell lines subjected to the same treatment a paired t-test was 
adopted. In order to assess a change over a period of time using a specific treatment, or to assess a 
change over a concentration range for a specific cell line a repeated measures one-way ANOVA table 
was used. When a comparison of two different time courses or concentration ranges was required a 
two-way ANOVA table was adopted. 
 
RESULTS 
Expression and palmitoylated state of wt-PAR2 and PAR2C361A. 
In order to study the potential role of palmitoylation in regulating PAR2 function, Pro5 cells were 
stably transfected with HA11-tagged wt-hPAR2 or hPAR2C361A where the putative palmitoylation 
site (C361) had been replaced with an alanine.  Receptor expressing cell lines were established and 
used at confluences which resulted in similar receptor expression as determined by flow cytometry 
(Figure 2). These were subsequently employed for further studies.  
Confocal imaging was used to identify the cellular localisation of receptor expression (Figure 
3). When stained with Sam11 anti-PAR2 antibody empty vector transfected cells (Figure 3A) showed 
no staining. Wt-hPAR2 (Figure 3B) and hPAR2C361A (Figure 3C) cells showed staining at the cell 
membrane. However, low levels of fluorescence were seen using this method and a high 
photomultiplier gain was required to observe any signal. Cells were therefore permeabilised and 
stained with anti-HA11 antibody.  Wt-hPAR2 (Figure 3E) displayed distinct, uniform and robust 
immunostaining around the cell membrane. Some punctate cytoplasmic staining was also observed.  
No staining was observed in the empty vector transfected cells (Figure 3D).  The staining pattern 
observed for hPAR2C361A (Figure 3F) was strikingly different to that of wt-hPAR2 (Figure 3E). The 
ring staining for hPAR2C361A was not uniform and distinct pockets of intense staining were observed 
at the cell surface. In addition considerable punctate staining was observed in the cytoplasmic region 
of the cells (Figure 3F). However, the staining for hPAR2C361A appeared brighter than that of wt-
PAR2. 
The palmitoylation state of the wt-hPAR2 and hPAR2C361A was then determined by 
metabolic labelling of the cells with [
3
H] palmitic acid followed by immunoprecipitation of the 
receptors.  Figure 4A shows that detectable levels of tritium were incorporated into wt-PAR2. Two 
broad smears were observed, one between ~50-75kDa and a second from ~25-30kDa. In contrast, 
PAR2C361A displayed an undetectable level of tritium incorporation. Western blot analysis of the 
same samples that were employed for the palmitoylation gel, demonstrated that approximately equal 
amounts of PAR2 protein were present in the wt-PAR2 and PAR2C361A samples (Figure 4B).  
 
Role of palmitoylation in regulating intracellular calcium signalling. 
To assess the importance of palmitoylation in regulating hPAR2 coupling to calcium, we compared 
the ability of wt-hPAR2 and hPAR2C361A to trigger increases in intracellular calcium in response to 
the hPAR2 agonists trypsin and SLIGKV-NH2. Trypsin and SLIGKV-NH2 concentration effect curves 
for hPAR2 and hPAR2C361A cell lines with matched expression (Figure 2) were constructed (Figure 
5).  For wt-hPAR2, both trypsin and SLIGKV-NH2 stimulated robust and similar maximal responses 
(~60% of A23187) at 316 nM, and 316 μM respectively (Figure 5). The EC50 for trypsin and 
SLIGKV-NH2 in activating wt-PAR2 was 11.44 nM and 15.69 μM respectively. In contrast to wt-
hPAR2, trypsin and SLIGKV-NH2 displayed significantly reduced efficacy towards hPAR2C361A 
(P=0.0003 and P=0.0058 respectively). The maximal obtainable responses to both trypsin and 
SLIGKV-NH2 were only ~50% and ~30% of that observed for wt-hPAR2 respectively (Figure 5). The 
hPAR2C361A EC50s for trypsin and SLIGKV-NH2 were 40.76 nM and 103.45 M respectively, 
displaying a 4 and 6 fold increase compared to that obtained for wt-hPAR2. 
 
Inhibition of Trypsin Mediated Calcium Signal by Pertussis Toxin. 
Pertussis toxin was used to ascertain what proportion of the total IP3 induced Ca
2+
 flux is due to 
signalling through Gi in wt-hPAR2 and the palmitoylation deficient mutant hPAR2C361A. PTX dose 
5 
 
dependently inhibited wt-hPAR2 and hPAR2C361A mediated calcium signalling to trypsin.  wt-
hPAR2 generated a maximum calcium signal of ~70% of A23187 decreasing to ~50% of A23187 at 
the maximum PTX concentration of 316 ng/ml (Figure 6). Whereas, hPAR2C361A produced a 
maximum calcium signal of ~30% of A23187 reducing down to <10% of A23187 at the maximum 
PTX concentration of 316 ng/ml. As such both curves reduce by ~20% of their A23187 signal (Figure 
6).  
 
Role of Palmitoylation in Regulating ERK1/2 Phosphorylation. 
Having established that the palmitoylation deficient hPAR2C361A mutant receptor coupled less 
efficiently to calcium, we asked whether receptor palmitoylation possibly regulated hPAR2 signalling 
to ERK1/2 (p44/42).  Significant differences in the pattern of the ERK1/2 stimulation were observed 
for hPAR2C361A compared to wt-hPAR2 (p<0.001) (Figure 7A). SLIGKV-NH2 stimulated a 
significantly greater degree of ERK1/2 phosphorylation in hPAR2C361A cells at the 5 and 10 min 
time points, and the ERK1/2 activation levels remaining significantly elevated up to the 60 min time 
point tested. Similarly, trypsin was also found to stimulate a significantly greater degree of ERK1/2 
phosphorylation through hPAR2C361A compared to wt-hPAR2 (P< 0.001) (Figure 7B). Trypsin 
stimulated a significantly greater degree of ERK1/2 phosphorylation in hPAR2C361A cells at the 5, 
10 and 20 min time points, and a more sustained ERK1/2 activation levels remaining significantly 
elevated up to the 60 min time point tested. All phosphorylated ERK1/2 blots were stripped of 
antibodies and re-probed with anti-total ERK1/2 and the phosphorylated ERK1/2 were then 
normalised against total ERK1/2 and expressed as a fold change of no treatment (NT). 
 
Inhibition of MAP Kinase Signalling by Pertussis Toxin 
To ascertain what proportion of the ERK signalling is due to signalling through Gi and to determine 
whether the lack of palmitoylation altered this signalling, wt-hPAR2, hPAR2C361A and empty vector 
control cells were preincubated with PTX before treating with PAR2 agonists (trypsin and SLIGKV).  
Trypsin and SLIGKV-NH2 evoked negligible changes in ERK1/2 signalling compared to NT 
in the empty vector cells (data not shown).   Treatment with PTX caused no significant change in 
ERK1/2 agonist induced signalling.  For wt-hPAR2 (Figure 8A) SLIGKV-NH2 and trypsin caused a 2 
and 1.5 fold increase in ERK1/2 signal over NT respectively.  Following pre-treatment with PTX 
there appeared to be a slight decrease in ERK1/2 signalling with all treatments though no significant 
difference was noted.  SLIGKV-NH2 and trypsin evoked a 2 and 3 fold increase in ERK1/2 signalling 
over NT respectively in hPAR2C361A expressing cells (Figure 8B).  When pre-treated with PTX 
ERK1/2 signalling in hPAR2C361A decreased a small amount following no treatment and trypsin 
treatment in comparison to samples not pre-treated with PTX. However, a large drop in ERK1/2 
signalling can be seen in the PTX pre-incubated SLIGKV-NH2 treated samples compared those not 
pre-incubated with PTX, though the changes are not statistically significant. 
 
Agonist Triggered Internalisation of PAR2. 
Flow cytometry was employed to determine the agonist induced internalisation of PAR2 using the 
monoclonal Sam11 antibody which recognises a sequence of the N-terminal domain that is located C-
terminal to the tethered-ligand [14](Figure 9). Thus, receptors that have been activated by trypsin can 
still be readily detected by this antibody [14]. As shown in figure 9, trypsin (100 nM) promoted rapid 
and significant (~50%) loss of cell surface wt-PAR2 by 10 min post agonist challenge. At the 60 min 
time point ~42% of wt-PAR2 was still detectable at the cell surface. Curiously, SLIGKV-NH2 (100 
M) only stimulated a modest loss of cell surface receptor at 30 and 60 min post agonist challenge. In 
contrast to wt-hPAR2, trypsin stimulated a significantly greater loss of hPAR2C361A from the cell 
surface at all time points tested, with over 81 ± 1.3% lost from the cell surface by 10 min post agonist 
challenge (P=0.016). Maximal loss of cell surface receptor was observed by 20 min (95 ± 2.6%) 
which thereafter remained unchanged up to the 60 min time point. As with wt-hPAR2 cells, we also 
observed only a minor degree of receptor internalisation with hPAR2C361A following treatment with 
SLIGKV-NH2 with maximal internalisation observed at 60 min (16 ± 2%). 
 
DISCUSSION 
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The data presented here provides the first direct biochemical and molecular evidence that hPAR2 is 
palmitoylated and that cysteine 361 is likely to be the primary site of palmitoylation. In addition 
evidence is presented here which demonstrates that palmitoylation of hPAR2 is a dynamic process that 
is influenced by agonist activation. Further, palmitoylation of hPAR2 was shown to regulate 
constitutive receptor expression, agonist triggered internalisation and more importantly inversely 
regulate receptor signalling to two major signalling pathways, namely calcium and MAPK.   
 The hPAR2C361A cell line displayed greater receptor expression than wt-hPAR2.  Removal 
of palmitoylation often results in loss of cell surface expression as seen with the V2 vasopressin 
receptor and CCR5 [15-17].  To our knowledge, this is the first study to find an increase in receptor 
expression resulting from the mutagenic removal of a palmitoylated cysteine. Possible reasons for 
increased receptor expression are covered later. 
Confocal microscopy was next employed to compare the cellular distribution of wt-hPAR2 
and hPAR2C361A.  Confocal imaging shows that PAR2 is located at the plasma membrane along with 
some internal localisation (which is greater in hPAR2C361A), this is presumably, at least in part, 
PAR2 contained in golgi stores, which is confirmatory of previous confocal imaging of PAR2 [18-20]. 
Immunoprecipitation of wt-hPAR2 and hPAR2C361A was carried out using the HA11 epitope 
tag, and western blotting carried out using anti-HA11 antibody as Sam11 does not work well with 
western blotting.  Immunoprecipitation was required as half of the sample was used to detect 
palmitoylation, it was therefore essential to remove unwanted (non-HA11 tagged) proteins.  The 
banding pattern seen is in keeping with the previous immunoblotting of hPAR2 [1] and the C361A 
appears to have no perceptible effect on the receptor molecular weight compared to wild-type. Despite 
flow cytometry data showing higher hPAR2C361A expression than the wild type, three times more 
cells were required to achieve matching quantities of receptor. However, if hPAR2 is palmitoylated at 
C361, the C361A mutation will result in a reduced C-terminal association with the cell membrane and 
potentially leave the C-terminus available to be more easily cleaved by endogenous proteases so 
removing the HA11 tag. Alternatively, the epitope may be obscured by the C-terminus becoming 
associated with different receptor domains, or sterically by an accessory protein binding to a nearby 
region on the C-terminus [21-22].   
Using direct biochemical labelling we provide compelling evidence that hPAR2 is 
palmitoylated. There is evidence that GPCRs can be palmitoylated in regions other than the C-
terminal tail [23]. However, since no [
3
H]-palmitate signal is evident in hPAR2C361A it seems likely 
this is the sole palmitoylation site for hPAR2.  
PAR2 palmitoylation has a significant effect on receptor mediated calcium signalling.  The 
decreased signal and agonist sensitivity observed for the hPAR2C361A mutant may be due to the 
revealing of phosphorylation sites within the C-terminus, which may normally be obscured by 
association with the membrane when palmitoylation is present. This is similar to the β-adrenergic 
receptor where substitution of the palmitoylated cysteine appears to allow agonist-independent 
phosphorylation of receptor PKA and GRK sites which would normally only phosphorylate upon 
activation [24].  In other GPCRs desensitisation/internalisation can be driven by phosphorylation 
dependent interations with β-arrestin [24-26]. Mutagenic replacement of the hPAR2 palmitoylation 
site may alternatively cause conformational change in the receptor leaving the tethered ligand and AP 
incapable of correctly binding to the ligand binding site. Although this has not previously been seen in 
the mutagenic replacement of palmitoylation, removal and mutagenesis of areas of the C-terminal tail 
in some GPCR have been shown to affect receptor folding [27-28]. The reduction in receptor 
mediated calcium signalling may be as a result of altered G-protein coupling. The C-terminal tail of 
many GPCRs are associated with G-protein coupling and as such removal of the palmitoylation site 
affects G-protein coupling in many GPCRs [24, 26, 29-30]. In some this is most likely because of 
increased phosphorylation [24-26, 31] but some mutagenically depalmitoylated GPCRs have 
decreased G-protein coupling without displaying increased phosphorylation [29, 32] suggesting 
another mechanism. 
Experiments assessing MAPK activation revealed that palmitoylation of PAR2 inversely 
regulates MAPK activation. This increased ERK1/2 signalling seen with the non-palmitoylated 
mutant may be due to increased β-arrestin association. It is well known that phosphorylation of the C-
terminus of PAR2 results in an increased affinity for β-arrestin binding which in turn uncouples the 
receptor from it’s G-protein by a steric mechanism [18-20]. Additionally, PAR2 expressed alongside a 
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β-arrestin mutant incapable of receptor binding shows diminished ability to activate ERK1/2 [18]. 
Studies on a number of GPCRs have now demonstrated that β-arrestins can mediate a number of 
signalling pathways independent of G-proteins [33-34]. Recently PAR2 activation has also been 
shown to promote β-arrestin actions-independent of G-proteins by direct inhibition of Gαq/11, as well 
as receptor coupling to Gαq/11 [35]. There is additional evidence to suggest that residues in the C-
terminus of PAR2 define specificity of β-arrestin binding and the duration of ERK1/2 association with 
β-arrestin [18, 36-37]. This combined with β-arrestin 1 and 2 association with ERK1/2 activation in 
the early and intermediate phases [38] supports the hypothesis that ERK1/2 signalling in 
hPAR2C361A maybe enhanced due to an increase in β-arrestin association. This increased β-arrestin 
association may also go to explain the increased receptor expression seen in hPAR2C361A compared 
to wt-hPAR2 as studies have shown a role for β-arrestins in trafficking of PAR2 from the golgi [35, 
38]  Further studies to investigate the role of β-arrestins in hPAR2C361A signalling,  expression and 
internalisation are required.  Alternatively, palmitoylation is linked with the targeting of receptors and 
signalling molecules alike to specific membrane microdomains such as lipid rafts [39-40]. It has been 
shown that Gαq interacts with caveolin, where as Gαi does not, suggesting they may therefore be 
targeted to different lipid regions [41]. The oxytocin receptor (OTR) is known to couple to both Gq 
and Gi but differentially activates one or the other depending on it’s membrane localisation [42]. 
When located within lipid rafts OTR activation results in cell growth through a Gq mediated pathway, 
when outside lipid rafts it results in Gi mediated inhibition of cell growth. This effect on cell growth is 
shown to be as a result of a different temporal pattern of EGFR and ERK1/2 phosphorylation, and is 
shown to be more persistent when receptors are located outside of lipid raft microdomains [42]. As 
such palmitoylation in hPAR2 may target the receptor to specific lipid raft microdomains, removal of 
which results in movement outside of these lipid rafts resulting in greater Gi association and 
prolonged ERK1/2 signalling. 
Palmitoylation has been shown to affect a GPCR ability to couple to its respective G-protein 
α subunit. For some GPCRs palmitoylation has been shown to selectively effect coupling to specific 
Gα subunits [29, 32] removing coupling to one or more subunits whilst maintaining coupling with 
another.  PTX, an inhibitor of signalling through Gi was used to further understand the effect of 
palmitoylation on PAR2 G-protein coupling calcium signalling. Interestingly calcium signalling of wt-
hPAR2 and hPAR2C361A was reduced by a similar magnitude, however in the mutant receptor, this 
reduction almost completely ablated the trypsin evoked calcium response suggesting signalling in 
hPAR2C361A is due to coupling with Gi.  Although previous GPCRs have shown selective 
uncoupling of Gα subunits [29, 32] these have preferentially lost Gi and maintained Gq coupling.  This 
was suggested by Okomoto et al as being due to Gi requiring a higher level of palmitoylation. 
However, if palmitoylation of hPAR2 targets the receptor to Gq containing lipid rafts, as with the OTR 
[42], and removal of palmitoylation results in the receptor locating outside of the raft then association 
with Gq would be disrupted. A recent study suggested that PAR2, unlike PAR1, does not signal 
through Gi [43], however in our cell system, it appears that in order to provoke calcium signalling 
hPAR2C361A couples to Gi.  Like DeFea et al we showed that hPAR2 activates ERK1/2 through a 
PTX insensitive pathway, so having little or no involvement by Gi [18].  In contrast, the non 
palmitoylated hPAR2C361A displayed reduced ERK phosphorylation post SLIGKV-NH2 activation, 
suggesting a Gi mediated response.  Numerous studies have shown ERK activation to be independent 
of G-protein signalling and PAR2 ERK signalling has been shown to be mediated by β-arrestin 
association [35, 38]. It maybe the increased association with Gi results in a shift in the preferred 
pathway for ERK1/2 activation. The signalling pathway responsible for activation of ERK in PAR2 
has previously been shown to “switch” in the case of PAR2δST363/366A, a phosphorylation deficient 
mutant, which activated ERK1/2 via a proline-rich tyrosine kinase-2 (PYK2) mediated pathway [18]. 
It was hypothesized that the interaction with the PYK2 pathway was a result of the prolonged Ca
2+
-
mobilisation observed in this mutant. As stated earlier Ca
2+
-mobilisation following hPAR2C361A 
activation takes longer to reach a signalling plateau so it maybe that the Gi-dependant activation of 
ERK1/2 activation observed is PYK2-mediated.  In addition to Gi and Gq, PAR2 is also thought to 
signal through G12/13 and Rho pathways [43].  Although we have not investigated these pathways here 
it would be interesting to determine the effect of PAR2 palmitoylation status on these pathways. 
The rate and extent of internalisation in response to trypsin is increased in the palmitoylated 
mutant compared to wt-hPAR2. However, neither mutant nor wild-type receptor showed 
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internalisation following treatment with SLIGKV-NH2. This is contrary to what has previously been 
reported for PAR2 following SLIGKV-NH2 treatment [18-20]. Internalisation rather than receptor 
degradation of PAR2 was confirmed by permeabolising cells and using endocytotic and PKC 
inhibitors concanavalin A and hyperosmolar glucose as well as fixing the membrane (data not shown).  
Hypertonic sucrose is known to prevent the recruitment of clathrin and interferes with normal coated-
pit formation and endocytosis [44-45], and concanavalin A is known to prevent the formation of 
coated pits [46-47]. As such we have also demonstrated that hPAR2 internalises by clathrin-coated 
pits, and hPAR2C361A internalises by the same mechanism albeit more rapidly.  Although this study 
is the first to report a differential effect of receptor cell surface expression and post-agonist 
endocytosis with trypsin and SLIGKV-NH2, the internalisation seen post-SLIGKV-NH2 treatment in 
previous publications maybe due to over-expression of β-arrestin in the cell lines used. A recent study 
has shown over-expression of β-arrestin to result in its constitutive association with cellular 
components [35]. 
Despite increased expression of hPAR2C361A compared to PAR2 in the resting state, with the 
addition of agonists the endocytosis of the mutant receptor appears increased over the wild type.  This 
enhanced post-activation endocytosis may be for a number of different reasons. If as previously 
discussed hPAR2C361A is constitutively phosphorylated then β-arrestin may associate with the 
receptor C-terminus. For the conformational change to occur in β-arrestin that allows high-affinity 
binding of AP-2 and clathrin, resulting in endocytosis, it must be bound to a receptor that is both 
phosphorylated and activated [48]. Since β-arrestin is already associated with the receptor upon 
activation, endocytosis can occur with fewer binding steps. If hPAR2 functions similarly to the OTR, 
then following activation the receptor depalmitoylates and needs to translocate from the caveolae 
domain before being endocytosed [42]. The removal of hPAR2 palmitoylation would mean the 
receptor was already located outside of the caveolae domain allowing clathrin binding and 
endocytosis without the need for receptor translocation. The increase in the amount of receptor 
endocytosed post-activation may occur as a result of uncoupling from Gq, phospholipase C (PLC) 
activity has previously been shown to inhibit endocytosis via clathrin-coated pits [49]. Since 
hPAR2C361A has reduced/abolished coupling to Gq, PLC activity would be significantly 
reduced/abolished so allowing increased endocytosis via clathrin-coated pits in the absence of 
inhibition from PLC. 
Upon activation the receptor must become depalmitoylated and phosphorylated before β-
arrestin binding. In order to mediate receptor endocytosis β-arrestin must undergo a conformational 
change which increases binding affinity of clathrin and AP-2 [48]. For this conformational change to 
occur the receptor must be both in an activated confirmation and phosphorylated [48]. Additionally, 
Receptor phosphorylation has previously been shown to be the rate limiting step for β-arrestin 
association [50]. As stated earlier it may be that the removal of palmitoylation results in the receptor 
being phosphorylated due the increased availability of the C-terminal phosphorylation sites, thus 
allowing β-arrestin binding but endocytosis does not occur until the receptor is activated. Since β-
arrestin is already associated with the receptor endocytosis can occur immediately without initial β-
arrestin association.  It would be interesting to prove this by further experimentation. 
This is the first study investigating the palmitoylation status of hPAR2 and its effect on 
receptor function. We have demonstrated that hPAR2 is palmitoylated pre-dominantly, if not entirely 
on C361. We have further demonstrated the multifaceted importance of palmitoylation on receptor 
expression, agonist sensitivity, densensitisation and internalisation. 
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FIGURE LEGENDS 
 
 Figure 1. Model in order to illustrate placement of haemagglutinin epitope tag (HA.11) and 
the four cysteine residues of interest. C361 is shown as a putative palmitoylation site and C148 and 
C226 are shown as putative sites for a disulphide bridge. 
 
 Figure 2. Assessment of receptor cell surface expression at varying cell confluences.  Pro5 
cells stably expressing wt-hPAR2 and hPAR2 C361A, were grown to confluence levels of 20 – 70% 
before harvesting and labelling with Sam11 anti-PAR2 antibody and anti-mouse FITC conjugate and 
analysing using flow cytometry.  Results are expressed as the mean ± SEM of 4 separate experiments. 
 
 Figure 3. Confocal images of wt-hPAR2 and hPAR2C361A localisation within the cell.  Cells 
were incubated with Sam11 anti-PAR2 primary antibody and anti-mouse FITC conjugated secondary 
antibody. Coverslips were then mounted and analysed by confocal microscopy.   (A) - pcDNA3.1 
empty vector. (B) - wt-hPAR2. (C) - hPAR2C361A.  Fixed and permeabilised cells were incubated 
with anti-HA11 primary antibody and anti-mouse FITC conjugated secondary antibody before 
analysing by confocal microscopy. (D) - pcDNA3.1 empty vector. (E) - Wt-hPAR2. (F) - 
hPAR2C361A.  Presence of PAR2 at the plasma membrane is indicated with arrowheads   .  PAR2 
contained internally is indicated with arrows .  Images shown are representative of three experiments 
 
Figure 4. [
3
H]- palmitate incorporation into wt-hPAR2 and hPAR2C361A. HA11-epitope 
immunoprecipitated protein preparations from empty vector, wt-hPAR2 and hPAR2C361A cells each 
labelled with 1 mCi [
3
H]-palmitate for 4 hours run on a 10% SDS-PAGE. Gel dried under vacuum 
and exposed to Hyperfilm™ x-ray film at -80oC for 6 weeks (A). A portion of the same samples were 
analysed on western blot using anti-HA11 antibody to assess receptor loading (B) and a 20 min 
exposure time. Blots shown are representative of three experiments. 
 
 Figure 5. Agonist concentration effect curves for wt-hPAR2 and hPAR2 C361A. Fluo3 loaded 
Pro5 cells stably expressing for wt-hPAR2 and hPAR2C361A were stimulated with increasing 
concentrations of trypsin or SLIGKV-NH2 and increases in intracellular calcium concentrations were 
measured. Results were expressed as a percentage of the maximum attainable response (response to 
A23187, calcium ionophore). Results are expressed as the mean ± SEM of 4 separate experiments. 
Each preformed in duplicate. 
 
 Figure 6. Graph showing inhibition of trypsin mediated Ca
2+
 release in wt-hPAR2 and 
hPAR2C361A. Changes in intracellular calcium levels were measured using a fluorospectrometer in 
fluo3 loaded wt- hPAR2 and hPAR2C361A Pro5 cells incubated with different concentrations of PTX 
(for 18 hours) prior to addition of 100 nM trypsin.  Values shown as a percentage of the maximum 
attainable response (response to A23187). 
 
 Figure 7. Agonist stimulated MAPK phosphorylation curves and representative 
phosphorylated and total p44/42 western blots. Graphs showing densitometric values for bands 
produced by western blot for phosphorylated p44/42 post-SLIGKV-NH2 treatment [A] and post 
trypsin treatment [B].  Normalised values are expressed as a fold change over no treatment (NT). 
Results are expressed as the mean ± SEM of 3 separate experiments, while the bands above are 
representative of the blots.  
 
Figure 8. Western blots and bar charts showing inhibition of MAPK with PTX. wt- hPAR2 
(A), and hPAR2C361A (B) cells were incubated with and without 100 ng/ml PTX (for 18 hours) prior 
to addition of 20 nM trypsin (Tryp) or 100 μM SLIGKV-NH2 (KV) or no treatment (NT) for 10 mins.  
13 
 
Cells were lysed using laemlli buffer before separating by 10% SDS-PAGE and immunoblotting.  
Normalised values are expressed as a fold change over no treatment (NT). A representative total 
p44/42 and anti-phospho p44/42 blot is shown above the respective histogram. Results expressed as 
the mean ± SEM of 3 separate experiments.  
 
Figure 9. Time course of receptor cell surface expression post-agonist addition. Pro5 cell 
stably expressing wt-hPAR2 and hPAR2 C361A were incubated with either 100 nM trypsin or 100 µM 
SLIGKV-NH2 for increasing periods of time before washing and labelling with Sam11 anti-PAR2 
antibody and anti-mouse FITC conjugate and analysed using flow cytometry.  Results are expressed 
as the mean ± SEM of 3 separate experiments 
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